Response of CD30+ Large Cell Lymphoma of Skin to Bexarotene
Yi-Kong Keung, Ralph D. Woodruff, Omar P. Sangüeza
Abstract
Yi-Kong Keung, Ralph D. Woodruff, Omar P. Sangüeza
Abstract
According to the REAL classification, CD30+ anaplastic large cell lymphoma of the skin is a distinct clinicopathologic entity characterized by an indolent clinical course. Mycosis fungoides are predominantly small cells with cerebriform nuclei and propensity to infiltrate the epidermis or epidermotropism. CD30+ lymphoid cells are not generally observed in mycosis fungoides except in late or terminal stage. To distinguish between CD30 positive anaplastic large cell lymphoma and CD30 positive mycosis fungoides may be difficult. We describe a case of CD30 positive large cell lymphoma of skin that responded to bexarotene that is recently approved for refractory mycosis fungoides.
OpenAlex reports 14 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
According to the REAL classification, CD30+ anaplastic large cell lymphoma of the skin is a distinct clinicopathologic entity characterized by an indolent clinical course. Mycosis fungoides are predominantly small cells with cerebriform nuclei and propensity to infiltrate the epidermis or epidermotropism. CD30+ lymphoid cells are not generally observed in mycosis fungoides except in late or terminal stage. To distinguish between CD30 positive anaplastic large cell lymphoma and CD30 positive mycosis fungoides may be difficult. We describe a case of CD30 positive large cell lymphoma of skin that responded to bexarotene that is recently approved for refractory mycosis fungoides.
Key concepts: Mycosis fungoides, Bexarotene, CD30, Anaplastic large-cell lymphoma, Brentuximab vedotin, Lymphoma, Cutaneous lymphoma, Medicine